Profile data is unavailable for this security.
About the company
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company’s products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
- Revenue in TWD (TTM)5.87bn
- Net income in TWD442.09m
- Incorporated2000
- Employees131.00
- LocationPharmaEssentia Corp13FNo.3, Yuanqu Street, Nankang DistrictTAIPEI 115TaiwanTWN
- Phone+886 226557688
- Fax+886 226557626
- Websitehttp://www.pharmaessentia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syngene International Ltd | 13.54bn | 1.98bn | 113.99bn | 6.51k | 57.71 | 6.89 | 31.38 | 8.42 | 12.68 | 12.68 | 86.75 | 106.24 | 0.5823 | 3.26 | 7.19 | 5,358,833.00 | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.13 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Shanghai Allist Pharmaceuticals Co Ltd | 11.08bn | 4.08bn | 124.90bn | 1.04k | 30.60 | 6.48 | -- | 11.27 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Telix Pharmaceuticals Ltd | 10.99bn | 113.99m | 135.12bn | 234.00 | 1,307.86 | 40.17 | 516.70 | 12.29 | 0.0141 | 0.0141 | 1.55 | 0.46 | 1.54 | 14.59 | 9.65 | -- | 1.59 | -29.21 | 2.54 | -40.27 | 62.56 | 61.64 | 1.04 | -37.14 | 1.32 | 24.03 | 0.1049 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Akeso Inc | 20.18bn | 9.04bn | 139.71bn | 2.78k | 14.95 | 6.49 | 15.03 | 6.92 | 2.60 | 2.60 | 5.81 | 6.00 | 0.6168 | 0.3749 | 15.98 | 1,750,867.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 6.87bn | -2.56bn | 151.04bn | 1.42k | -- | 14.31 | -- | 22.00 | -2.78 | -2.78 | 7.55 | 11.42 | -- | -- | -- | 1,169,903.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Biocon Ltd | 57.26bn | 3.97bn | 171.94bn | 3.41k | 43.35 | 2.25 | 15.46 | 3.00 | 8.54 | 8.54 | 123.32 | 164.78 | 0.273 | 1.07 | 3.01 | -- | 2.40 | 3.20 | 3.50 | 4.48 | 66.81 | 63.27 | 8.80 | 9.37 | 0.6664 | 1.63 | 0.3917 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| PharmaEssentia Corp | 5.87bn | 442.09m | 193.29bn | 131.00 | 411.63 | 7.71 | 258.28 | 32.92 | 1.38 | 1.38 | 18.17 | 73.56 | 0.2681 | 0.5024 | 4.64 | -- | 2.02 | -16.79 | 2.32 | -19.66 | 88.58 | 76.47 | 7.53 | -79.56 | 11.67 | -- | 0.0444 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
| WuXi Biologics (Cayman) Inc | 75.93bn | 15.15bn | 193.97bn | 12.74k | 13.40 | 1.10 | 8.78 | 2.55 | 0.84 | 0.84 | 4.21 | 10.22 | 0.321 | 5.04 | 3.02 | 1,436,813.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
Data as of Jul 08 2024. Currency figures normalised to PharmaEssentia Corp's reporting currency: Taiwan Dollar TWD
7.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Jun 2024 | 9.32m | 2.73% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 6.21m | 1.82% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.46m | 1.01% |
| BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 1.56m | 0.46% |
| Geode Capital Management LLCas of 03 Jul 2024 | 1.14m | 0.33% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 897.06k | 0.26% |
| State Street Global Advisors Ltd.as of 06 Jun 2024 | 595.98k | 0.18% |
| Handelsbanken Fonder ABas of 30 Jun 2024 | 528.00k | 0.16% |
| Royal London Asset Management Ltd.as of 31 Mar 2024 | 450.00k | 0.13% |
| Sjunde AP-fondenas of 30 Apr 2024 | 418.00k | 0.12% |
More ▼
Data from 31 Dec 2023 - 04 Jul 2024Source: FactSet Research Systems Inc.
